Who
Adrian W. Quartel
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Spruce Biosciences; Chief Medical Officer, Zevra Therapeutics; Chief Medical Officer, Acer Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $80K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 21 Feb 2022
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K4,533 at $8.83 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K4,533 at $8.83 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 30 Jan 2025filed 27 Mar 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 30 Jan 2025filed 27 Mar 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 14 Mar 2023filed 16 Mar 2023 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 21 Feb 2022filed 23 Feb 2022 | Acer Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.